Company intelligence / Profile preview
STINGINN
United Statesstinginn.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
STINGINN is developing pre-clinical STING activators (SA-001) for anti-tumor/anti-viral use and inhibitors (SI-001) for anti-inflammatory use; HTLV-1 vaccine and STING-activating oncolytic viruses advancing toward Phase I trials with STTR funding.[1][5]
- Therapeutic areas
- ImmunologyNeurologyInfectious DiseasesRheumatologyRare DiseasesGastroenterologyOncology
- Modalities
- Small moleculeNucleic acid-based STING activatorsOncolytic virusVaccine
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Vyriad (exclusive license for STING technology)University of Miami (STTR collaboration)
Beyond the preview
Go deeper on STINGINN.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STINGINN.